Cargando…
Combination of AZD3463 and DZNep Prevents Bone Metastasis of Breast Cancer by Suppressing Akt Signaling
Osteolysis resulting from osteoclast overactivation is one of the severe complications of breast cancer metastasis to the bone. Previous studies reported that the anti-cancer agent DZNep induces cancer cell apoptosis by activating Akt signaling. However, the effect of DZNep on breast cancer bone met...
Autores principales: | He, Wenxin, Cao, Xiankun, Rong, Kewei, Chen, Xiaojun, Han, Shuai, Qin, An |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193724/ https://www.ncbi.nlm.nih.gov/pubmed/34122074 http://dx.doi.org/10.3389/fphar.2021.652071 |
Ejemplares similares
-
DZNep promotes mouse bone defect healing via enhancing both osteogenesis and osteoclastogenesis
por: Cao, Xiankun, et al.
Publicado: (2021) -
AZD3463, an IGF-1R inhibitor, suppresses breast cancer metastasis to bone via modulation of the PI3K-Akt pathway
por: Hu, Guang-Fu, et al.
Publicado: (2020) -
Ceritinib (LDK378) prevents bone loss via suppressing Akt and NF-κB-induced osteoclast formation
por: He, Wenxin, et al.
Publicado: (2022) -
The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
por: Moharram, Sausan A., et al.
Publicado: (2019) -
Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis
por: Wang, Yongfeng, et al.
Publicado: (2016)